High-throughput screening with CETSA

16 May 2024

High-throughput cellular thermal shift assays (CETSA®) are increasingly adopted earlier in the drug discovery pipeline due to rapid development times and the capability to generate primary hit material for challenging targets. Targets such as p53 can be considered challenging or ‘undruggable’ for a multitude of reasons such as lack of tools, assays, lack of enzyme activity or cellular localization. With CETSA HT screening, challenging targets are prosecuted in their native environment without any modification. Pelago Bioscience highlights how CETSA can be implemented into drug discovery pipelines and presents supportive results from numerous assays.